10-Q quarterly report · filed Nov 5, 2026

PULSE BIOSCIENCES, INC. (PLSE) Q3 2026 10-Q Quarterly Report

Short answer

PULSE BIOSCIENCES, INC. (PLSE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $395,000 (up 359.3% year over year) with net income of −$23M.

Q3 2026 key financials · XBRL

Revenue
$395,000
+359.3% YoY · −9.0% QoQ
Net income
−$23M
−18.9% YoY · +6.5% QoQ
Operating margin
-6149.9%
EPS (diluted)
−$0.32
−14.3% YoY · +11.1% QoQ

Source: XBRL data from the PULSE BIOSCIENCES, INC. (PLSE) Q3 2026 10-Q on SEC EDGAR. USD.

PULSE BIOSCIENCES, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0.4M, up $0.3M YoY from $0.1M, entirely from limited Vybrance sales
  • Operating margin not disclosed; operating loss $24.3M vs $20.4M YoY
  • Vybrance best-performing product line, revenue $0.4M versus $0.1M YoY
  • Cash, equivalents and marketable securities $189.2M; operating cash use $48.6M for nine months
  • Management expects additional losses, plans near-term capital raising, cites financing access and market conditions as headwinds

Risk Factors

  • New AI compliance risk triggered by expanded internal use of generative AI and machine learning, including EU AI Act and evolving FDA requirements
  • Regulatory review delays heightened by FDA workforce reductions, voluntary departures, and policy uncertainty since January 2025
  • Near-term adoption risk: surgeons have been slow to adopt the Vybrance System due to limited clinical data and reimbursement uncertainty
  • Liquidity risk: additional capital required, with armed conflicts and tariffs potentially restricting financing availability or increasing dilution
  • Cybersecurity risk: limited resources and no redundant information technology across all systems increase vulnerability to disruptive incidents

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other PULSE BIOSCIENCES, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.